<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=A_Disputes_Over_Contentious_Otenabant-Practices</id>
		<title>A Disputes Over Contentious Otenabant-Practices - Історія редагувань</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=A_Disputes_Over_Contentious_Otenabant-Practices"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=A_Disputes_Over_Contentious_Otenabant-Practices&amp;action=history"/>
		<updated>2026-05-06T03:15:36Z</updated>
		<subtitle>Історія редагувань цієї сторінки в вікі</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=A_Disputes_Over_Contentious_Otenabant-Practices&amp;diff=121877&amp;oldid=prev</id>
		<title>Curleregypt6: Створена сторінка: 1 (p?[https://en.wikipedia.org/wiki/Otenabant Otenabant] important pathogen. The analysis was performed in unique settings of two rehabilitation centres in Ital...</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=A_Disputes_Over_Contentious_Otenabant-Practices&amp;diff=121877&amp;oldid=prev"/>
				<updated>2016-12-16T03:11:11Z</updated>
		
		<summary type="html">&lt;p&gt;Створена сторінка: 1 (p?[https://en.wikipedia.org/wiki/Otenabant Otenabant] important pathogen. The analysis was performed in unique settings of two rehabilitation centres in Ital...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Нова сторінка&lt;/b&gt;&lt;/p&gt;&lt;div&gt;1 (p?[https://en.wikipedia.org/wiki/Otenabant Otenabant] important pathogen. The analysis was performed in unique settings of two rehabilitation centres in Italy and Israel that differed significantly in the types of medical services and their patient populations. These differences were probably responsible for the differences in risk factors for the ESBL-PM carriage identified in each centre. In Italy, ESBL-PM carriers differed in many aspects from the control group of patients. Several risk factors that were identified, including longer LOS and recent treatment with quinolones, were previously described as risk factors for other ESBL-Ent infections [34]. The use of an invasive device was identified as a risk factor in the univariate analysis, as reported by Endimiani et?al. [2], but previous LTCF admission was not. We also did not identify recent treatment with cephalosporins and anti-pseudomonas penicillin as risk factors, as reported in a retrospective study of nosocomial multidrug-resistant (MDR) P.?mirabilis urinary tract infection [1]. We identified admission following SABI as an independent risk factor. As this feature is unique to that particular [http://www.selleckchem.com/products/mi-773-sar405838.html MI-773 cell line] institution (FSL, Rome), it has not been reported or sought in other studies. Although local spread might have been a plausible explanation for this finding, it was not supported by the polyclonal nature of the ESBL-PM isolates in this group of patients (data not shown). A unique finding in our study was the identification of decubitus ulcer as another independent risk factor. As P.?mirabilis is commonly isolated from chronic wounds [35], this finding may reflect [http://www.selleckchem.com/products/lee011.html click here] a complex interaction between the intestinal and the wound flora in these patients. In the Israeli centre, TASMC, several risk factors were identified but, in contrast to FSL, these were statistically non-significant (0.05?&lt;/div&gt;</summary>
		<author><name>Curleregypt6</name></author>	</entry>

	</feed>